Interesting DXC Put And Call Options For September 18th

DXC (current price $14.91) option ideas: a $14 put trading with a $0.15 bid would leave a net cost basis of $13.85 if sold-to-open, is ~6% out-of-the-money, carries a 66% chance of expiring worthless and yields 1.07% (1.59% annualized) if it does. The $16 call bid is $0.35 for a covered-call trade that would deliver a 9.66% total return if called at the Sept. 18 expiration, is ~7% out-of-the-money, and has a 46% chance of expiring worthless (2.35% boost, 3.48% annualized). Implied volatilities are elevated (put 55%, call 52%) versus trailing 12-month realized volatility of 42%, suggesting premium-rich option pricing for income strategies.

Analysis

Market-structure: The options market signals a mildly favorable seller edge—DXC spot $14.91 vs Sep18 $14 put bid $0.15 (66% OTM-expire probability) and $16 call bid $0.35 (46% OTM-expire). Implied vol (52–55%) vs realized 42% implies ~30% relative overpricing of short-dated premium, favoring premium-selling strategies for investors who accept assignment at $13.85. Liquidity and skew matter: low open interest or wide spreads would reduce effective yields.

Risk assessment: Tail risks include a surprise operational miss or credit event that could push DXC >20% lower in weeks (breaching ~$12), at which point short-put sellers face rapid mark-to-market losses; regulatory/contract losses for IT-services firms are lower probability but high impact. Near-term (days–weeks) key risks are IV spikes and earnings; medium-term (months) hinge on business-restructuring cadence and cash-flow recovery; long-term depends on margin improvement and client retention.

Trade implications: Direct actionable plays are cash-secured $14 puts (collector) and covered-call overlays on purchased stock to synthetically compress entry cost to $13.85–$14.56. Prefer defined-risk structures (put spreads or buy-down protection) rather than naked short strangles. If you expect mean-reversion in vol, sell Sep dashed premium, size 1–3% portfolio, and cap downside via buy-$12 protection.

Contrarian angles: Consensus focuses on modest yields, but with IV/RV divergence the market is likely overstating near-term event risk; selling premium is underpriced if fundamentals stay stable. Conversely, if liquidity thins or an idiosyncratic restructuring accelerates, premium sellers will be whipsawed—so prefer capped-risk credit spreads or assignment-ready cash allocation rather than naked short exposure.

Key Decisions for Investors

• Sell cash-secured DXC $14 Sep18 put for ~$0.15 if bid fills; size to 1–2% of portfolio (i.e., cash reserved for assignment = $14×contracts). Target cost basis $13.85; close or roll if DXC < $13.00 or IV rises >20 pts from entry.
• Buy DXC up to 2–3% position at market ($~14.9) and sell Sep18 $16 covered call for ~$0.35 to capture 2.35% immediate premium (9.66% to strike if called). Close if stock >$16 or drops below $13.50 (cut to half-size).
• If wanting defined risk, sell Sep18 $14/$12 put credit spread (receive ~0.15–0.20 net) sized 1–3% portfolio; max loss = $2 minus premium. Exit/roll if DXC < $12.50 or spread cost >50% of max loss.
• Deploy a small volatility arbitrage: sell short-dated premium (Sep) versus buy further-dated protection (3–6 month $12–$13 put) to monetize IV term-structure; limit allocation to 0.5–1% and reassess after next earnings or material company update.